Typhoid Fever Vaccines Market, By Vaccine Type (Live Attenuated Vaccine, Capsular Polysaccharide Vaccines, Conjugate Vaccine), Mode of Administration (Oral, Parental), and By Region (North America, Europe, Asia Pacific, Middle East & Africa, and South America) – Market Size & Forecasting To 2028

COVID-19 Impact : Our team has been closely monitoring the current developments to identify the potential impact of COVID-19 on stakeholders and business processes across the value chain of industries. A special section about COVID-19 will be covered with the report to help companies in defining sustainable strategies.

Global Typhoid Vaccines Market, by Vaccine Type, was valued at USD 225.0 million in 2019 and is projected to exhibit a CAGR of 11.9% during the forecast period 2028. Increasing government initiatives for raising awareness regarding typhoid vaccines and supporting access to new vaccines are expected to support the worldwide typhoid vaccines market growth.

Active involvement by organizations like GAVI Alliance (Global Alliance for Vaccines and Immunisation), UNICEF (The United Nations International Children's Emergency Fund), WHO (World Health Organization), et al. in increasing accessibility of those vaccines in emerging economies is further expected to fuel typhoid vaccines market growth. For example, in April 2018, GAVI designated US$ 85 million to fund the introduction of the Typbar TCV (Bharat Biotech) vaccine in low-income countries across Africa and Asia region. Moreover, there are several typhoid conjugate vaccines present within the pipeline, which are expected to enter within the market over the forecast period. In October 2017, WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) re-emphasized the importance of typhoid vaccines in low- and middle-income countries, also as for the control of endemic typhoid. Moreover, the Typhoid Vaccine Acceleration Consortium (TyVAC) – which is a partnership between University of Maryland School of Vaccine Types, University of Oxford and PATH – is currently conducting clinical trials for Typbar TCV prequalified vaccine in Malawi, Nepal, and Bangladesh to further evaluate clinical efficacy and potential of the vaccine in reducing typhoid burden in these countries. Furthermore, the introduction of clinically simpler typhoid vaccines in niche sectors (such as India) also as internationally has supported the growth of the market. For example, Vivotif (oral vaccine), a clinically simpler Typhim Vi (WHO prequalified in 2011), and now Typbar TCV (first conjugate vaccine WHO prequalified in 2017) are now available within the market.

Key Insights of Typhoid Fever Vaccines Market:

  • The number of increasing Typhoid cases across the globe along with lack of adequate medical infrastructure in developing nations are expected to be the major driver boosting the market growth over the forecast period
  • The global typhoid vaccines market is predicted to exhibit a highest CAGR during the forecast period (2020 – 2028), due to frequent product launches and approvals, and a robust pipeline of novel typhoid vaccines
  • Asia Pacific typhoid vaccine market is predicted to account for the largest market share, due to the high prevalence of typhoid. for example, consistent with the info published by Medindia around 18,45,997 cases of typhoid were found in India in 2015
  • North America's typhoid vaccine market is predicted to point out stagnant growth over the forecast period, due to the low prevalence of typhoid in the region. For example, consistent with the info published by the Centers for Disease Control and Prevention (CDC) 2017, around 300 culture-confirmed cases of typhoid and 80 cases of paratyphoid caused by S. enterica serotype Paratyphi A are reported annually within the U.S.
  • Major players operating within the typhoid vaccines market include GlaxoSmithKline Plc., Sanofi SA, Bharat Biotech, Bio-Med Pvt. Ltd., PT Bio Farma, PaxVax Inc., Shanghai Institute of Biological Products Co. Ltd., and Prokarium

The Typhoid Fever Vaccines market segmentation is based on vaccine type, mode of administration, and region.

Vaccine Type Outlook:

In terms of product, typhoid vaccines are of 4 types viz. Ty21a, Vi capsular polysaccharide vaccine, Vi Conjugate (Vi-TT), and Vi Conjugate (Vi-REPA). Ty21a are a live vaccine and Vi capsular polysaccharides are a sub-unit vaccine. The other two types are restricted to the niche sectors that they don't have global acceptance. For example, Vi Conjugate (Vi-TT) is licensed just for the market in India.

Mode of Administration Outlook:

Based on the mode of administration, the typhoid vaccine market is often segmented into oral or injectable. For example, Ty21a is taken orally, while Vi capsular polysaccharide vaccine is injectable. By delivery channel, the typhoid vaccines market are often classified into hospitals, pharmacies, and clinics/health care centers related to government programs. The inflow of patients to hospitals is predicted to extend during the forecast period, as hospitals are considered to be more reliable and that they have an outsized number of suppliers, reimbursement authority, and government support. Based on end-users, the typhoid vaccines market has been segmented into pediatrics and adults.

Regional Outlook:

Based on geography, the worldwide typhoid vaccine market has been divided into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the main share of the typhoid vaccine market in terms of revenue in 2019. This is primarily due to increasing awareness among people within the region, which results in the increase in demand for vaccination to infants, children, and adults. Also, the easy availability of vaccines within the U.S. and favorable government initiatives for vaccination programs fuel the typhoid vaccine market within the region. The marketplace for typhoid vaccines in the Asia Pacific is predicted to expand at the greatest CAGR during the forecast period, thanks to government initiatives for immunization against typhoid and enormous population base, especially in China and India. China is expected to steer the Asia Pacific typhoid vaccine market during the forecast period, due to an increase in government support for vaccination and rise within the number of individuals with typhoid disease within the region. Brazil is expected to be a prominent marketplace for typhoid vaccines in Latin America by 2028. The developing health care infrastructure and interest of key players in investing in Brazil by establishing manufacturing units within the region are major factors driving the typhoid vaccine market in Brazil. GCC dominates the typhoid vaccine market within the Middle East, whereas, South Africa holds the leading share of the market in Africa. The typhoid vaccine market in Africa is experiencing strong growth, thanks to the rapid rise in vaccination programs, frequent typhoid outbreaks within the region, and increasing investments by major players.

  • High prevalence of typhoid in the region like the Asia Pacific and Africa is predicted to drastically raise demand for its vaccines and support global typhoid vaccines market growth over the forecast period.
  • For instance, consistent with the info published by the World Health Organization (WHO) in September 2018, globally between 11 and 21 million cases of typhoid were found, which caused around 128 000 to 161 000 typhoid-related deaths to occur annually.
  • According to the info published by the National Center for Biotechnology Information (NCBI) in 2018, the incidence of typhoid in Africa was estimated to be 10–100 cases per 100,000
  • Increasing initiatives by government and various other organizations to extend awareness about typhoid vaccine and rising access to the latest vaccines is predicted to support typhoid vaccine market growth during the forecast period.

Competitive Landscape

Key players operating within the global typhoid vaccines market include AstraZeneca, GlaxoSmithKline plc, Merck & Co. Inc., Pfizer, Inc., Sanofi, and Johnson & Johnson.

Key Developments in Typhoid Fever Vaccines Market:

  • In February 2019, Gavi, the Vaccine Alliance in partnership with WHO, CDC and Zimbabwe’s Ministry of Health launched a campaign to tackle the typhoid outbreak in Zimbabwe. The campaign aims to vaccinate 325,000 people in nine suburbs of Zimbabwe’s capital with a new typhoid conjugate vaccine (TCV).

What Does This Report Provide?

This report provides a detailed understanding of the global Typhoid Fever Vaccines market from qualitative and quantitative perspectives during the forecast period. The report also provides dynamic indicators with potential impact on the market during the forecast period and an in-depth analysis of the leading companies operating in the market.

Market Segmentation:

By Vaccine Type

  • Live Attenuated Vaccine
  • Capsular Polysaccharide Vaccines

By Mode of Administration

  • Oral
  • Parental

By Region:

  • North America
    • By Country (US, Canada, Mexico)
    • By Vaccine Type
    • By Mode of Administration
  • Europe
    • By Country (Germany, Russia, UK, France, Italy, Spain, Rest of Europe)
    • By Vaccine Type
    • By Mode of Administration
  • Asia Pacific
    • By Country (China, Japan, India, South Korea, Australia, Rest of Asia Pacific)
    • By Vaccine Type
    • By Mode of Administration
  • The Middle East and Africa
    • By Country (UAE, Saudi Arabia, Qatar, South Africa, Rest of the Middle East and Africa)
    • By Vaccine Type
    • By Mode of Administration
  • South America
    • By Country (Brazil, Argentina, Colombia, Rest of South America)
    • By Vaccine Type
    • By Mode of Administration

Reasons to Buy This Report:

  • Market size estimation of the Typhoid Fever Vaccines market on a regional and global basis
  • Unique research Usage for market size estimation and forecast
  • Profiling of major companies operating in the market with key developments
  • Broad scope to cover all the possible segments helping every stakeholder in the market


We provide customization of the study to meet specific requirements:

  • By Segment
  • By Sub-segment
  • By Region/Country

For more information, contact:  sales@quincemarketinsights.com